Results 151 to 160 of about 827 (180)
Some of the next articles are maybe not open access.
Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
Annals of Pharmacotherapy, 2023Objective: To review the pharmacology, efficacy, and safety of intravenous sulbactam-durlobactam (SUL-DUR) in the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Data Sources: PubMed databases and ClinicalTrials.gov were searched using the following terms: Sulbactam Durlobactam, ETX2514, Xacduro, Sulbactam-ETX2514 ...
Benjamin August +2 more
openaire +2 more sources
Sulbactam/Durlobactam: First Approval
Drugs, 2023Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Coadministration of durlobactam (a β-lactamase inhibitor with potent activity against a broad range of serine β-lactamases) with ...
openaire +2 more sources
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics, 2023The FDA has approved Xacduro (Innoviva), a combination of the beta-lactam antibacterial sulbactam and the beta-lactamase inhibitor durlobactam, for IV treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC).
openaire +2 more sources
Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex
Expert Review of Anti-Infective TherapyInfections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.This review provides a comprehensive discussion of ...
Jordan R Covvey, Anthony J Guarascio
exaly +3 more sources
American Journal of Health-System Pharmacy, 2023
Abstract Purpose Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y ...
Victor H, Ruiz +5 more
openaire +2 more sources
Abstract Purpose Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y ...
Victor H, Ruiz +5 more
openaire +2 more sources
The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections
Current Opinion in Infectious DiseasesPurpose of review Infections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles.
Bassetti, Matteo +3 more
openaire +3 more sources
International Journal of Antimicrobial Agents
The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for A. baumannii.In 2023, 504 nonduplicated A. baumannii isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard ...
Xiaolan Hong +7 more
openaire +2 more sources
The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for A. baumannii.In 2023, 504 nonduplicated A. baumannii isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard ...
Xiaolan Hong +7 more
openaire +2 more sources
American Journal of Therapeutics
Background: Antimicrobial resistance (AMR) is a major health crisis specifically associated with Acinetobacter. Among different Acinetobacter species, Acinetobacter baumannii is known as the greatest culprit concerning clinical significance. Of most importance, carbapenem-resistant A.
Nino Marzella +4 more
openaire +1 more source
Background: Antimicrobial resistance (AMR) is a major health crisis specifically associated with Acinetobacter. Among different Acinetobacter species, Acinetobacter baumannii is known as the greatest culprit concerning clinical significance. Of most importance, carbapenem-resistant A.
Nino Marzella +4 more
openaire +1 more source
Diagnostic Microbiology and Infectious DiseaseCombinations of the β-lactam/β-lactamase inhibitor sulbactam-durlobactam and seventeen antimicrobial agents were tested against strains of Acinetobacter baumannii in checkerboard assays. Most combinations resulted in indifference with no instances of antagonism. These results suggest sulbactam-durlobactam antibacterial activity against A.
Alita A Miller +2 more
exaly +3 more sources